The Pouch Revolution: How a Swedish Tradition Became Big Tobacco's Escape Hatch

In 2023, Philip Morris International paid $16 billion to acquire Swedish Match—a company whose flagship product is not a cigarette, not a vape, but a small white pouch containing nicotine powder, cellulose, and flavoring, placed between the upper lip and gum. The acquisition was the clearest signal yet that the nicotine industry's future is moving from the lungs to the mouth. Nicotine pouches—led by Swedish Match's ZYN brand, which has become a cultural phenomenon in the US—represent a category that barely existed five years ago and now generates over $10 billion in annual global revenue. The pouch revolution is not just a product trend. It's a strategic pivot that is reshaping the competitive landscape of the nicotine industry.

The appeal of nicotine pouches is not hard to understand. They're discreet—no vapor, no odor, no need to step outside. They're tobacco-free, which matters for regulatory classification and consumer perception. They come in a range of flavors and nicotine strengths, from 1.5mg to 12mg and above, allowing users to self-titrate. They don't require devices, batteries, or maintenance. For smokers who find vaping unsatisfying or socially awkward, pouches offer an alternative that sidesteps the lung entirely. And for never-smokers—a controversial but undeniable driver of pouch growth—the low barrier to trial (a can costs $4-6, no device purchase required) combined with the discreet format makes pouches easier to experiment with than any previous nicotine product.

The competitive dynamics are fascinating. Swedish Match, now part of PMI, owns the US market with ZYN commanding roughly 70% share. Altria, having divested its stake in Juul after the youth-vaping crisis cratered the brand's value, has entered the pouch market with 'on!'—a product that has struggled to gain traction against ZYN's dominance but provides Altria with a foothold in the category. British American Tobacco markets Velo (formerly Lyft) globally, with a strong presence in Europe and Africa. Imperial Brands markets Zone X. The major cigarette companies, having watched the vaping market fragment under regulatory pressure and competition from Chinese disposables, are placing a second bet: that pouches, with their simpler supply chain, lower regulatory profile, and higher margins, are the more sustainable path to a smoke-free future.

The regulatory outlook for pouches is uncertain but cautiously optimistic from an industry perspective. Because pouches contain no tobacco leaf, they occupy a regulatory category that is simpler to navigate than vaping products—at least for now. FDA regulates them as 'tobacco products' under the same statutory framework as cigarettes and vapes, but the PMTA pathway for pouches is less burdensome than for vaping products, given the simpler chemical profile and the absence of inhalation-related health concerns. Several pouch products have received FDA marketing authorization. The potential wildcard is taxation: some states have begun imposing e-cigarette taxes on pouches, and a dedicated 'nicotine tax' at the federal level has been proposed. But the overall trajectory is toward regulatory acceptance, not rejection—particularly as public health agencies recognize that pouches, like snus before them, are dramatically less harmful than cigarettes.

The cultural dimension of the pouch phenomenon deserves attention. ZYN has become, in certain demographic niches—young, male, often involved in finance, tech, or military—a lifestyle product with its own vernacular ('Zynners,' 'zynning,' 'upper-deckies'). This cultural embedding is a double-edged sword for the industry. On one hand, it drives organic growth and brand loyalty that no marketing budget can buy. On the other, it attracts exactly the kind of public attention—'is this product creating a new generation of nicotine users?'—that leads to regulatory crackdowns. The industry is walking a tightrope: promoting pouches as a harm reduction tool for smokers while managing the reality that a significant share of pouch users are not former smokers. The narrative that has worked for Swedish Match in Sweden for decades—'this is how Swedes quit smoking'—may not survive in a US market where pouches are increasingly a starter product, not a switcher product.

For the cigarette companies, pouches represent something that vaping never fully delivered: a product that can actually replace cigarette revenue. Vaping's economics are challenging—low barriers to entry, intense price competition, a fragmented supply chain, and regulatory uncertainty. Pouches are different. They're cheaper to manufacture than vaping devices, have higher repeat-purchase rates, face less competition from low-cost Chinese manufacturers, and generate margins that are comparable to cigarettes. If the major companies can transition their cigarette consumers to pouch consumers—and early evidence from ZYN's US growth suggests they can—the economic case for a smoke-free future becomes much stronger. The pouch revolution is, at its core, a business-model revolution.

Shareable insight: The cigarette industry isn't dying—it's migrating. The destination isn't vaping, which is too fragmented and too regulated. It's the oral nicotine pouch, which combines high margins, high loyalty, and a format that regulators are still figuring out.